Research Highlights

COVID Breaking news: CNS injury biomarkers elevated in COVID patients

New randomised control trial evidence for treatment of status epilepticus

A new guideline on the palliative care for people with severe multiple sclerosis has been produced by EAN, in collaboration with ...

A double-blind, randomised, placebo-controlled phase II study of adjunctive cenobamate in adults with uncontrolled focal epilepsy showed high rates of total seizure-freedom over 12 weeks.

This neurology update summarises key points on caring for people with epilepsy during the COVID-19 pandemic.

Seizures appear to be a rare feature of COVID-19. Avoiding unintentional antiseizure medicine withdrawal during the COVID-19 pandemic is a potential challenge for people with epilepsy.

Neurologists stay aware of COVID-19 brain stem involvement The major clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection are due to pulmonary complications. The majority of the patients so far in the COVID-19 pandemic had milder symptoms… Continue Reading

Cutaneous silent periods Cutaneous silent period is a useful, although underestimated tool for the clinical assessment of poly neuropathy as well as other neurological condition. This review provides an up to date on the physiology and methodology for its use… Continue Reading

Breaking news in Neuro-Oncology

Tranexamic Acid administered after Traumatic Brain Injury may reduce mortality

Vagal nerve stimulation may improve post-stroke motor recovery

Expanding the expansions in hereditary ataxias

Multiple system atrophy (MSA) is a rare, fatal, neurodegenerative disease of the adulthood presenting with progressive autonomic failure, parkinsonian, cerebellar and pyramidal features in various combinations.

Findings suggest narcolepsy type 1 to be a T-cell mediated autoimmune disease targeting hypocretin-producing neurons.

Nakalanga syndrome: Clinical characteristics, potential causes, and its relationship with recently described Nodding syndrome